CORRECTING and REPLACING Hanshow Strengthens Global Ecosystem by Partnering with Glintt Life and shopreme to Drive Smart Retail Digitalization
24.9.2025 13:00:00 CEST | Business Wire | Press Release
Please replace the release with the following corrected version due to multiple revisions.
The updated release reads:
HANSHOW STRENGTHENS GLOBAL ECOSYSTEM BY PARTNERING WITH GLINTT LIFE AND SHOPREME TO DRIVE SMART RETAIL DIGITALIZATION
Hanshow, a global leader in digital retail solutions, is deepening its global ecosystem through strategic collaborations that connect local market expertise with advanced retail technology. The latest partnerships bring together Glintt—a technology and distribution powerhouse in the Iberian pharmacy sector—and shopreme, a leading provider of self-checkout and smart-cart solutions. Rather than parallel initiatives, these relationships plug into one architecture that links digital pricing, in-store media, checkout innovation, and sector-specific workflows to accelerate smart retail digitalization at scale.
Through its companies Pulso and Consoft, responsible for the pharmacy management software Nixfarma and Farmatic, Glintt Life connects more than 12,000 pharmacies across Spain with platforms that support prescriptions, logistics, and services. This solid footprint, combined with Glintt Life’s track record in healthcare digitalization, positions the brand as a trusted partner to bring Hanshow’s retail innovations into the pharmacy channel. “Our partnership with Hanshow enables us to bring intelligent retail tools into pharmacies, transforming how healthcare providers serve patients with efficiency and personalization,” said Luis Esgueva, Executive at Glintt Global and responsible for the Glintt Life pharmacy business in Spain.
shopreme's unified self-checkout ecosystem, deployed in over 2,000 stores worldwide, complements Hanshow's smart cart tablets and in-store media with its snap cart software. For retailers, the result is retrofit-ready, scalable, and GDPR-compliant—reducing shrinkage, enhancing the shopping journey, and opening new retail-media monetization opportunities. “By joining forces with Hanshow, we’re creating a future-ready checkout model that blends customer convenience with operational efficiency and new in-store media capabilities,” said Nico Müller, CCO at shopreme.
Hanshow’s ecosystem approach extends across regions and categories through long-standing relationships with local leaders and specialized innovators. In Southern Europe, ICS Karafyllis S.A. supports fiscal solutions and POS services across Greece and Cyprus; throughout Europe, Shop&Roll contributes shopping-transport, visual-merchandising, and POS equipment with award-winning sustainable designs; in the Middle East, Arab Mechanical Engineers enables retailers to adopt and scale digital in-store technologies. Together with Glintt Life and shopreme, these partners operate as connected nodes in a single network—localizing quickly, compounding value, and shortening time-to-impact for retailers worldwide.
“We are excited to advance this ecosystem alongside partners such as Glintt Life and shopreme in Europe, ICS Karafyllis S.A. in Greece and Cyprus, Shop&Roll across European markets, Arab Mechanical Engineers in the Middle East, and other regional innovators,” said Liangyan Li, Senior Vice President at Hanshow. “By uniting local reach with Hanshow’s digital capabilities—from ESL and in-store media to seamless checkout—we’re helping retailers lower costs, enhance efficiency, and accelerate sustainable, customer-focused transformation across the global marketplace.”
About Glintt Life
Glintt Life, a brand of Glintt Global dedicated to the healthcare sector, is the Iberian leader in health technology. Committed to a connected and global health ecosystem, it supports healthcare professionals in fulfilling their purpose of improving citizens’ quality of life. With over 30 years of healthcare expertise and a 360º portfolio for the pharmacy and hospital sectors, Glintt Life develops, implements, and supports a wide range of services and solutions across more than 14,000 pharmacies and 430 hospitals in Portugal and Spain.
Anchored in the company’s strong internal expertise and its constant investment in powerful and emerging technologies, Glintt Life technologically connects everything related to health.
Because health is everything — and everything in health must be connected.
Glintt Life. care for tomorrow
Learn more:glinttlife.com
About shopreme
shopreme is a leading provider of self-checkout solutions, offering a comprehensive portfolio of innovative technologies to enhance the retail shopping experience. With solutions such as Scan & Go, SCO, AI-based Loss Prevention, and Smart Cart, shopreme is revolutionizing the way customers shop and pay in brick-and-mortar stores – in more than 2,000 stores worldwide. For more information, please click here.
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow’s solutions have provided services to a vast number of stores in over 70 countries and regions, helping them streamline operations, optimize pricing strategies, and offer customers a more personalized experience. Learn more : www.hanshow.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250923729516/en/
Contacts
info@hanshow.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom